SEARCH:   Advanced

Blood, 16 April 2009, Vol. 113, No. 16, pp. 3809-3812. Prepublished online as a Blood First Edition Paper on February 4, 2009; DOI 10.1182/blood-2008-10-185280. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-10-185280v1 113/16/3809    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hilchey, S. P. Articles by Bernstein, S. H. Search for Related Content PubMed PubMed Citation Articles by Hilchey, S. P. Articles by Bernstein, S. H. Related Collections Immunobiology Free Research Articles Lymphoid Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  LYMPHOID NEOPLASIA Brief report Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab Shannon P. Hilchey1, Ollivier Hyrien1, Tim R. Mosmann2, Alexandra M. Livingstone2, Jonathan W. Friedberg1, Faith Young1, Richard I. Fisher1, Raymond J. Kelleher, Jr3, Richard B. Bankert3, and Steven H. Bernstein1 1 James P. Wilmot Cancer Center and 2 David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, and Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester, NY; and 3 Witebsky Center for Microbial Pathogenesis and Immunology, School of Medicine, State University of New York at Buffalo The incorporation of rituximab, a chimeric anti-CD20 monoclonal antibody, into the therapeutic armamentarium for patients with follicular lymphoma (FL) has significantly improved treatment outcome for such patients. Despite the almost universal application of this therapy, however, its exact mechanism of action has not been completely defined. One proposed mechanism is that of a "vaccinal" effect, whereby FL cell kill by rituximab results in the elicitation of an FL-specific T-cell response. The demonstration that rituximab can even elicit such a response in patients has, to our knowledge, never been shown. We analyzed the response against the immunoglobulin expressed by the FL before and after rituximab monotherapy in 5 FL patients and found an increase in FL idiotype–specific T cells after rituximab in 4 of 5 patients. Our data thus provide "proof of principle" for the ability of passive immunotherapy with rituximab to elicit an active FL-specific cellular response. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. G. Ramsay, A. J. Clear, G. Kelly, R. Fatah, J. Matthews, F. MacDougall, T. A. Lister, A. M. Lee, M. Calaminici, and J. G. Gribben Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy Blood, November 19, 2009; 114(21): 4713 - 4720. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020